Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations
The purpose of this study is to determine the rate of progression free survival of patients with inoperable cholangiocarcinoma 6 months after enrollment in the study. The patients are treated with combination chemotherapy supplemented by biological agents panitumumab or bevacizumab.
Cholangiocarcinoma
DRUG: Gemcitabine|DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Panitumumab|DRUG: Bevacizumab
The fraction of patients alive and without progression at 6 months, 6 months from enrollment date
Response rate before cross-over, 6 months after enrollment or earlier in case of progression|Overall survival, 6 months|Progression free survival and response rate after cross-over, 6 months
The purpose of this study is to determine the rate of progression free survival of patients with inoperable cholangiocarcinoma 6 months after enrollment in the study. The patients are treated with combination chemotherapy supplemented by biological agents panitumumab or bevacizumab.